A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (NCT06735248)
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of mRNA-1195 Intramuscular Injection in Participants 18 to ≤55 Years of Age With Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Who can join: Review the eligibility criteria below.
Location: Boston Clinical Trials Inc - Internal Medicine — Boston, Massachusetts
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Boston Clinical Trials Inc - Internal Medicine — Boston, Massachusetts
- Quest Research Institute — Farmington Hills, Michigan
- Sharlin Health & Neurology — Ozark, Missouri
- Washington University School of Medicine Neurology Clinical Unit — St Louis, Missouri
- Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence — Oklahoma City, Oklahoma
- University of Texas Southwestern Medical Center — Dallas, Texas
- ANESC Research — El Paso, Texas
- Saturn Research Solutions — Plano, Texas
- University of the Sunshine Coast Clinical Trials — Birtinya, Queensland
- North Bristol NHS Trust - Southmead Hospital — Bristol,
- Cardiff and Vale University Health Board - University Hospital Wales — Cardiff,
- Anne Rowling Regenerative Neurology Clinic, University of Edinburgh — Edinburgh,
- NHS Greater Glasgow & Clyde - Institute of Neurological Sciences — Glasgow,
- Cambridge Clinical Research Centre — London,
- East Kent Hospitals University NHS Foundation Trust — London,
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust — Newcastle upon Tyne,
- Sheffield Teaching Hospital NHS foundation Trust, Herries Road — Sheffield,
📞 Contact the Study Coordinator
Phone: (866) 663-3762
Email: WeCareClinicalTrials@modernatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.